Treatment | N | Total CUA cases | N | Dialysis cases | N | Non dialysis cases |
---|---|---|---|---|---|---|
Wound care | 89 | 88 (98.9%) | 70 | 70 (100.0%) | 19 | 18 (94.7%) |
Antibiotherapy | 89 | 69 (77.5%) | 70 | 53 (75.7%) | 19 | 16 (84.2%) |
Discontinuation of VKA | 65 | 46 (70.8%) | 54 | 38 (70.4%) | 11 | 8 (72.7%) |
Discontinuation of active vitamin D | 20 | 14 (70.0%) | 17 | 11 (64.7%) | 3 | 3 (100.0%) |
Intravenous STS | 89 | 58 (65.2%) | 70 | 45 (64.3%) | 19 | 13 (68.4%) |
STS cumulative dose (g) | 56 | 488 (300–750) | 43 | 525 (300–750) | 13 | 375 (225–900) |
STS duration (week) | 58 | 6 (4–10) | 45 | 6 (4–10) | 13 | 5 (3–12) |
Renal Replacement Therapy modification | 89 | 57 (64.0%) | ||||
Increase of dialysis duration and/or frequency | 70 | 41 (58.6%) | ||||
Start of dialysis | 19 | 16 (84.2%) | ||||
Switch from HD to HDF | 70 | 13 (18.6%) | ||||
Switch from HDF to HD | 70 | 4 (5.7%) | ||||
Use of citrate dialysate | 89 | 6 (6.7%) | 70 | 6 (8.6%) | 19 | 0 (0.0%) |
Discontinuation or lowering of oral calcium supply | 53 | 31 (58.5%) | 46 | 26 (56.5%) | 7 | 5 (71.43%) |
Nutritional support therapy | 89 | 47 (52.8%) | 70 | 35 (50.0%) | 19 | 12 (63.2%) |
Sevelamer | 89 | 42 (47.2%) | 70 | 31 (44.3%) | 19 | 11 (57.9%) |
Initiation or dose increase of Sevelamer | 89 | 24 (27.0%) | 70 | 15 (21.4%) | 19 | 9 (47.4%) |
Initiation or dose increase of Cinacalcet | 89 | 31 (34.8%) | 70 | 27 (38.6%) | 19 | 4 (21.1%) |
Discontinuation of native vitamin D | 52 | 18 (34.6%) | 40 | 12 (30.0%) | 12 | 6 (50.0%) |
Surgical debridement | 89 | 22 (24.7%) | 70 | 17 (24.3%) | 19 | 5 (26.3%) |
≥ 2 surgical debridement | 89 | 9 (10.1%) | 70 | 8 (11.4%) | 19 | 1 (5.26%) |
Amputation | 89 | 15 (16.9%) | 70 | 13 (18.6%) | 19 | 2 (10.5%) |
Lanthanum carbonate | 89 | 15 (16.9%) | 70 | 15 (21.4%) | 19 | 0 (0.0%) |
Initiation or dose increase of Lanthanum carbonate | 89 | 7 (7.9%) | 70 | 7 (10.0%) | 19 | 0 (0.0%) |
Negative pressure wound therapy | 89 | 12 (13.5%) | 70 | 8 (11.4%) | 19 | 4 (21.1%) |
Discontinuation of iron therapy | 62 | 8 (12.9%) | 54 | 7 (13.0%) | 8 | 1 (12.5%) |
Standard oxygen therapy | 89 | 11 (12.4%) | 70 | 9 (12.9%) | 19 | 2 (10.5%) |
Initiation or dose increase of statin | 89 | 10 (11.2%) | 70 | 8 (11.4%) | 19 | 2 (10.5%) |
Skin transplantation | 89 | 8 (9.0%) | 70 | 7 (10.0%) | 19 | 1 (5.3%) |
Parathyroidectomy | 89 | 5 (5.6%) | 70 | 5 (7.1%) | 19 | 0 (0.0%) |
Steroids | ||||||
Discontinuation or dose decrease of steroids | 12 | 7 (58.3%) | 10 | 6 (60.0%) | 2 | 1 (50.0%) |
Initiation or dose increase of steroids | 12 | 2 (16.7%) | 10 | 2 (20.0%) | 0 | 0 (0.0%) |
Local steroids treatement | 89 | 12 (13.5%) | 70 | 9 (12.9%) | 19 | 3 (15.8%) |